Sample Solution

• Dysfunctional uterine bleeding constitutes a considerable problem for many women causing discomfort and decreased quality of life. About 10-15% of women experience episodes of dysfunctional uterine bleeding at sometime during the reproductive years of their lives. It is a common cause of iron deficiency anaemia in healthy fertile female[3].

• Annually 5-10% of women of reproductive age seek medical care for DUB which negatively impacts quality of life. Over all it accounts for 6.2% of genitourinary disease reporting to outpatient department and may account for more than 25% of all hysterectomies [4]

• A wide range of treatment modalities are available for dysfunctional uterine bleeding which include medical therapy and surgical interventions. Pharmacological management can be hormonal or non hormonal. Non hormonal drugs like NSAID’S, ethamsylate and antifibrinolytics have been found to be highly effective. Hormonal agents include progestins, combined OCP’s, danazol, GnRH agonists, latest SERMs, oestrogens, sometimes androgens, Levonorgestrel IUCD.

• RCOG recommends beginning with medical management before resorting to surgical intervention[4].

• Medical management has always been the first therapeutic option to be tried as it is less complicative, less morbidity, and economical. For medical management many drugs are available. Each drug has its own advantages, disadvantages, side effects.

• Ormeloxifene a non steroidal selective estrogen receptors modulator and has been used for past 20years as an oral contraceptive. It is good option for menorrhagia leading to 77-85% reduction in menstrual blood loss and causes amenorrhea in 17-42% patients.[1]

• Ormeloxifene is a benzopyram SERM, which blocks the cytosol rec